Skip to content Skip to footer
Subscribe Now
NEWS

Chiesi Group Enters a ~$2.1B Deal with Arbor Biotechnologies to Develop Novel Rare Disease Gene Editing Programs

Shots:Chiesi Group has entered into an exclusive global collaboration & license deal with Arbor for ABO-101 in primary hyperoxaluria type 1 (PH1) & a multitarget option to use Arbor’s gene editing platform for developing liver-targeted therapies for rare diseasesAs per the deal, Chiesi will obtain exclusive rights to develop & commercialize ABO-101 for PH1…
October 7, 2025

Read more

Intellia Therapeutics
NEWS

Intellia Reports Long-Term P-I Trial Data of Nexiguran Ziclumeran for Hereditary ATTR Amyloidosis with Polyneuropathy (ATTRv-PN)

Shots:Intellia has reported P-I trial data assessing nexiguran ziclumeran (nex-z) in ATTRv-PN; results were presented at the International ATTR Amyloidosis Meeting 2025 & published in The NEJMSingle dose of nex-z achieved mean TTR reductions of 92% at 24mos. & 90% in 12 pts followed for 36mos. At 24mos., 13/18 pts met ≥4-point mNIS+7 improvement, incl.…
September 26, 2025

Read more

Intellia Therapeutics
NEWS

Intellia Therapeutics Completes Enrollment in the P-III (HAELO) Study of Lonvoguran Ziclumeran (lonvo-z) in Hereditary Angioedema (HAE) Patients

Shots:Intellia Therapeutics completed enrollment in the global P-III (HAELO) study evaluating lonvo-z for treating HAE, finishing within 9mos. since the first patient was dosed in Jan 2025, with nearly half of the participants enrolled from the USThe study P-III (HAELO) study will evaluate the efficacy and safety of lonvo-z in ≥60 adults and…
September 19, 2025

Read more

ThoughtSpot_Saurabh Chaubey5
THOUGHTSPOT

4 Biopharma Trends to Watch out in 2024

Shots: 2023 had been a great year for the biopharma industry despite several imposed restrictions from the IRA and inflation With several swaying factors impacting the biopharma industry, including social, economic, regulatory and others, some of the noteworthy trends that emerged in 2024 and are shaping the ways biopharma companies operate The article explores four key…
July 9, 2024

Read more